Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details

Pfizer Inc. (PFE) on Monday said that it will acquire biopharmaceutical company Metsera (MTSR) for $47.50 per share in cash at closing.

The upfront purchase price of $47.50 per share represents a premium of 43% from Metsera’s closing share price on Friday. The deal represents a total enterprise value of approximately $4.9 billion for Metsera.

Metsera shareholders will also receive a non-transferable contingent value right (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. The transaction is expected to close in the fourth quarter of 2025, subject to the satisfaction of customary closing conditions.

Shares of Metsera soared 59% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around MTSR jumped from ‘bullish’ to ‘extremely bullish' territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.

New York City-based Metsera is a clinical-stage biopharmaceutical company developing medicines for obesity and cardiometabolic diseases.

Pfizer said on Monday that the proposed acquisition will add four highly differentiated clinical-stage programs to Pfizer’s pipeline, including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist, and MET-233i, a monthly amylin analog candidate, in addition to two other oral GLP-1 receptor agonists expected to begin clinical trials soon. GLP-1 receptor agonists are a class of medications that mimic the effects of the body's natural hormone glucagon-like peptide-1 (GLP-1) to treat type 2 diabetes and obesity. Amylin analogs, likewise, can lead to weight loss.

“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,” said Pfizer CEO Albert Bourla. Pfizer scrapped its own obesity drug candidate, Danuglipron, earlier this year.

The Financial Times had on Sunday reported that the two companies could announce a deal as early as Monday.

While Pfizer’s stock has declined 9% so far in 2025, Metsera’s stock has risen 25.7% over the same period.

Read also: Micron Stock Gets A Price Target Hike From Stifel Ahead Of Q4 Earnings – Find Out More

For updates and corrections, email newsroom[at]stocktwits[dot]com.